➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Harvard Business School
Medtronic
Colorcon
AstraZeneca

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,436,185


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,436,185 protect, and when does it expire?

Patent 8,436,185 protects ZEJULA and is included in one NDA.

This patent has twenty patent family members in fifteen countries.

Summary for Patent: 8,436,185
Title:Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Abstract: The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl) transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA-damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy.
Inventor(s): Foley; Jennifer R. (Garwood, NJ), Wilson; Robert Darrin (Hoddesdon Herts, GB)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/811,922
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,436,185

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline ZEJULA niraparib tosylate CAPSULE;ORAL 208447-001 Mar 27, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,436,185

PCT Information
PCT FiledJanuary 08, 2009PCT Application Number:PCT/GB2009/000041
PCT Publication Date:July 16, 2009PCT Publication Number: WO2009/087381

International Family Members for US Patent 8,436,185

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009203598 ⤷  Free Forever Trial
Brazil PI0906020 ⤷  Free Forever Trial
Canada 2711491 ⤷  Free Forever Trial
China 101932572 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Baxter
Boehringer Ingelheim
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.